Pharmaniaga Bhd (KLSE: PHARMA) has taken a major step forward on its turnaround journey after completing its regularisation plan, positioning the group for a potential PN17 exit by 1QCY2026. This development has caught the attention of analysts, with MBSB Research upgrading Pharmaniaga to a “Buy” call and setting a target price (TP) of RM0.32. Regularisation […]
